Top

Published in:

Open Access 01-12-2024 | Idiopathic Pulmonary Fibrosis | Research

ILD-GAP combined with the monocyte ratio could be a better prognostic prediction model than ILD-GAP in patients with interstitial lung diseases

Authors: Momo Hirata, Yu Hara, Hiroaki Fujii, Kota Murohashi, Yusuke Saigusa, Shiqi Zhao, Miyu Kobayashi, Ryo Nagasawa, Yoichi Tagami, Ami Izawa, Yukiko Otsu, Keisuke Watanabe, Nobuyuki Horita, Nobuaki Kobayashi, Takeshi Kaneko

Published in: BMC Pulmonary Medicine | Issue 1/2024

Abstract

Background

The ILD-GAP scoring system is known to be useful in predicting prognosis in patients with interstitial lung disease (ILD). An elevated monocyte count was associated with increased risks of IPF poor prognosis. We examined whether the ILD-GAP scoring system combined with the monocyte ratio (ILD-GAPM) is superior to the conventional ILD-GAP model in predicting ILD prognosis.

Methods

In patients with ILD treated between April 2013 and April 2017, we were retrospectively assessed the relationships between baseline clinical parameters, including age, sex, Charlson Comorbidity Index score (CCIS), ILD diagnosis, blood biomarkers, pulmonary function test results, and disease outcomes. In ILD patients were included idiopathic pulmonary fibrosis (IPF), idiopathic nonspecific interstitial pneumonia (iNSIP), collagen vascular disease-related interstitial pneumonia (CVD-IP), chronic hypersensitivity pneumonitis (CHP), and unclassifiable ILD (UC-ILD). We also assessed the ability to predict prognosis was compared between the ILD-GAP and ILD-GAPM models.

Results

A total of 179 patients (mean age, 73 years) were assessed. All of them were taken pulmonary function test, including percentage predicted diffusion capacity for carbon monoxide. ILD patients included 56 IPF cases, 112 iNSIP and CVD-IP cases, 6 CHP cases and 5 UC-ILD cases. ILD-GAPM provided a greater area under the receiver-operating characteristic curve (0.747) than ILD-GAP (0.710) for predicting 3-year ILD-related events. Furthermore, the log-rank test showed that the Kaplan-Meier curves in ILD-GAPM were significantly different by stage (P = 0.015), but not by stage in ILD-GAP (P = 0.074).

Conclusions

The ILD-GAPM model may be a more accurate predictor of prognosis for ILD patients than the ILD-GAP model.

Available only for authorised users

Travis WD, Costabel U, Hansell DM, King TE Jr, Lynch DA, Nicholson AG, Ryerson CJ, Ryu JH, Selman M, Wells AU, Behr J, Bouros D, Brown KK, Colby TV, Collard HR, Cordeiro CR, Cottin V, Crestani B, Drent M, Dudden RF, Egan J, Flaherty K, Hogaboam C, Inoue Y, Johkoh T, Kim DS, Kitaichi M, Loyd J, Martinez FJ, Myers J, Protzko S, Raghu G, Richeldi L, Svarzellati N, Swigris J, Valeyre D. An official American Thoracic Society/European Respiratory Society statement: update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med. 2013;188:733–48.CrossRefPubMedPubMedCentral

Baratella E, Ruaro B, Giudici F, Wade B, Santagiuliana M, Salton F, Confalonieri P, Simbolo M, Scarpa A, Tollot S, Marrocchio C, Cova MA, Confalonieri M. Evaluation of correlations between genetic variants and high-resolution computed tomography patterns in idiopathic pulmonary fibrosis. Diagnostics (Basel). 2021;11:762.CrossRefPubMedPubMedCentral

Kondoh Y, Myers J, Müller NL, Nicholson AG, Richeldi L, Selman M, Dudden RF, Griss BS, Protzko SJ, Schünemann HJ. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med. 2011;183:788–824.CrossRefPubMedPubMedCentral

Raghu G, Remy-Jardin M, Richeldi L, Thomson CC, Inoue Y, Johkoh T, Kreuter M, Lynch DA, Maher TM, Martinez FJ, Molina-Molina M, Myers JL, Nicholson AG, Ryerson CJ, Strek ME, Troy LK, Wijsenbeek M, Mammen MJ, Hossain T, Bissell BD, Herman DD, Hon SM, Kheir F, Khor YH, Macrea M, Antoniou KM, Bouros D, Buendia-Roldan I, Caro F, Crestani B, Ho L, Morisset J, Olson AL, Podolanczuk A, Poletti V, Selman M, Ewing T, Jones S, Knight SL, Ghazipura M, Wilson KC. Idiopathic pulmonary pibrosis (an update) and progressive pulmonary fibrosis in adults: an official ATS/ERS/JRS/ALAT clinical practice guideline. Am J Respir Crit Care Med. 2022;205:e18–47.CrossRefPubMedPubMedCentral

Ley B, Ryerson CJ, Vittinghoff E, Ryu JH, Tomassetti S, Lee JS, Poletti V, Buccioli M, Elicker BM, Jones KD, King TE Jr, Collard HR. A multidimensional index and staging system for idiopathic pulmonary fibrosis. Ann Intern Med. 2012;156:684–91.CrossRefPubMed

Ryerson CJ, Vittinghoff E, Ley B, Lee JS, Mooney JJ, Jones KD, Elicker BM, Wolters PJ, Koth LL, King TE Jr, Collard HR. Predicting survival across chronic interstitial lung disease: the ILD-GAP model. Chest. 2014;145:723–8.CrossRefPubMed

Kishaba T, Tamaki H, Shimaoka Y, Fukuyama H, Yamashiro S. Staging of acute exacerbation in patients with idiopathic pulmonary fibrosis. Lung. 2014;192:141–9.CrossRefPubMed

Murohashi K, Hara Y, Saigusa Y, Kobayashi N, Sato T, Yamamoto M, Kudo M, Kaneko T. Clinical significance of Charlson comorbidity index as a prognostic parameter for patients with acute or subacute idiopathic interstitial pneumonias and acute exacerbation of collagen vascular diseases-related interstitial pneumonia. J Thorac Dis. 2019;11:2448–57.CrossRefPubMedPubMedCentral

Yagyu H, Murohashi K, Hara Y, Saigusa Y, Aoki A, Kobayashi N, Kaneko T. Clinical utility of a composite scoring system including Charlson comorbidity index score in patients with interstitial lung disease. J Thorac Dis. 2020;12:5774–82.CrossRefPubMedPubMedCentral

10.

Pastre J, Barnett S, Ksovreli I, Taylor J, Brown AW, Shlobin OA, Ahmad K, Khangoora V, Aryal S, King CS, Nathan SD. Idiopathic pulmonary fibrosis patients with severe physiologic impairment: characteristics and outcomes. Respir Res. 2021;22:5.CrossRefPubMedPubMedCentral

11.

Confalonieri P, Volpe MC, Jacob J, Maiocchi S, Salton F, Ruaro B, Confalonieri M, Braga L. Regeneration or repair? The role of alveolar epithelial cells in the pathogenesis of idiopathic pulmonary fibrosis (IPF). Cells. 2022;11:2095.CrossRefPubMedPubMedCentral

12.

Zinellu A, Collu C, Nasser M, Paliogiannis P, Mellino S, Zinellu E, Traclet J, Ahmad K, Mangoni AA, Carru C, Pirina P, Fois AG, Cottin V. The aggregate index of systemic inflammation (AISI): a novel prognostic biomarker in idiopathic pulmonary fibrosis. J Clin Med. 2021;10:4134.CrossRefPubMedPubMedCentral

13.

Michael K, Lee JS, Tzouvelekis A, Oldham JM, Molyneaux PL, Weycker D, Mark A, Kirchgaessler KU, Maher TM. Monocyte count as a prognostic biomarker in patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2021;204:74–81.CrossRef

14.

Moua T, Westerly BD, Dulohery MM, Daniels CE, Ryu JH, Lim KG. Patients with fibrotic interstitial lung disease hospitalized for acute respiratory worsening: a large cohort analysis. Chest. 2016;149:1205–14.CrossRefPubMed

15.

Hyzy R, Huang S, Myers J, Flaherty K, Martinez F. Acute exacerbation of idiopathic pulmonary fibrosis. Chest. 2007;132:1652–8.CrossRefPubMed

16.

Lacasse Y, Selman M, Costabel U, Dalphin JC, Ando M, Morell F, Erkinjuntti-Pekkanen R, Muller N, Colby TV, Schuyler M, Cormier Yvon HP Study Group. Clinical diagnosis of hypersensitivity pneumonitis. Am J Respir Crit Care Med. 2003;168:952–8.CrossRefPubMed

17.

Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40:373–83.CrossRefPubMed

18.

Tominaga T, Nonaka T, Takeshita H, Kunizaki M, Sumida Y, Hidaka S, Sawai T, Nagayasu T. The Charlson comorbidity index as an independent prognostic factor in older colorectal cancer patients. Indian J Surg. 2018;80:54–60.CrossRefPubMed

19.

Zhao L, Leung LH, Wang J, Li H, Che J, Liu L, Yao X, Cao B. Association between Charlson comorbidity index score and outcome in patients with stage IIIB-IV non-small cell lung cancer. BMC Pulm Med. 2017;17:112.CrossRefPubMedPubMedCentral

20.

Núñez JE, Núñez E, Fácila L, Bertomeu V, Llàcer A, Bodí V, Sanchis J, Sanjuán R, Blasco ML, Consuegra L, Martínez A, Chorro FJ, et al. Prognostic value of Charlson comorbidity index at 30 days and 1 year after acute myocardial infarction. Rev Esp Cardiol. 2004;57:842–9.CrossRefPubMed

21.

Ooi GC, Mok MY, Tsang KW, Wong Y, Khong PL, Fung PC, Chan S, Tse HF, Wong RW, Lam WK, Lau CS. Interstitial lung disease in systemic sclerosis. Acta Radiol. 2003;44:258–64.PubMed

22.

Scott MKD, Quinn K, Qin L, Carroll R, Warsinske H, Vallania F, Chen S, Carns MA, Aren K, Sun J, Koloms K, Lee J, Baral J, Kropski J, Zhao H, Herzog E, Martinez F, Moore BB, Hinchcliff M, Denny J, Kaminski N, Herazo-Maya JD, Shah NH, Khatri P. Increased monocyte count as a cellular biomarker for poor outcomes in fibrotic diseases: a retrospective, multicentre cohort study. Lancet. Respir Med. 2019;7:497–508.

23.

Teoh AKY, Jo HE, Chambers DC, Symons K, Walters EH, Goh NS, Glaspole I, Cooper W, Reynolds P, Moodley Y, Corte TJ. Blood monocyte counts as a potential prognostic marker for idiopathic pulmonary fibrosis: analysis from the Australian IPF registry. Eur Respir J. 2020;55:1901855.CrossRefPubMed

24.

Misharin AV, Morales-Nebreda L, Reyfman PA, Cuda CM, Walter JM, McQuattie-Pimentel AC, Chen CI, Anekalla KR, Joshi N, Williams KJN, Abdala-Valencia H, Yacoub TJ, Chi M, Chiu S, Gonzalez-Gonzalez FJ, Gates K, Lam AP, Nicholson TT, Homan PJ, Soberanes S, Dominguez S, Morgan VK, Saber R, Shaffer A, Hinchcliff M, Marshall SA, Bharat A, Berdnikovs S, Bhorade SM, Bartom ET, Morimoto RI, Balch WE, Sznajder JI, Chandel NS, Mutlu GM, Jain M, Gottardi CJ, Singer BD, Ridge KM, Bagheri N, Shilatifard A, Budinger GRS, Perlman H. Monocyte-derived alveolar macrophages drive lung fibrosis and persist in the lung over the life span. J Exp Med. 2017;214:2387–404.CrossRefPubMedPubMedCentral

25.

Gordon S. Alternative activation of macrophages. Nat Rev Immunol. 2003;3:23–35.CrossRefPubMed

26.

Aggarwal NR, King LS, D’Alessio FR. Diverse macrophage populations mediate acute lung inflammation and resolution. Am J Physiol Lung Cell Mol Physiol. 2014;306:L709–25.CrossRefPubMedPubMedCentral

27.

Nouno T, Okamoto M, Ohnishi K, Kaieda S, Tominaga M, Zaizen Y, Ichiki M, Momosaki S, Nakamura M, Fujimoto K, Fukuoka J, Shimizu S, Komohara Y, Hoshino T. Elevation of pulmonary CD163+ and CD204+ macrophages is associated with the clinical course of idiopathic pulmonary fibrosis patients. J Thorac Dis. 2019;11:4005–17.CrossRefPubMedPubMedCentral

28.

Yamashita M, Saito R, Yasuhira S, Fukuda Y, Sasamo H, Sugai T, Yamauchi K, Maemondo M. Distinct profiles of CD163-positive macrophages in idiopathic interstitial pneumonias. J Immunol Res. 2018;2018:1436236.CrossRefPubMedPubMedCentral

29.

Schupp JC, Binder H, Jäger B, Cillis G, Zissel G, Müller-Quernheim J, Prasse A. Macrophage activation in acute exacerbation of idiopathic pulmonary fibrosis. PLoS One. 2015;10:e0116775.CrossRefPubMedPubMedCentral

30.

Murohashi K, Hara Y, Shinada K, Nagai K, Shinkai M, Kawana A, Kaneko T. Clinical significance of serum hemeoxygenase-1 as a new biomarker for the patients with interstitial pneumonia. Can Respir J. 2018;2018:7260178.CrossRefPubMedPubMedCentral

31.

Mendonça Almeida L, Fernandes AL, Gouveia Cardoso C, Lima B, Neves I, Novais-Bastos H, Caetano Mota P, Melo N, Souto Moura C, Guimarães S, Carvalho A, Cunha R, Pereira JM, Morais A. Mortality risk prediction with ILD-GAP index in a fibrotic hypersensitivity pneumonitis cohort. Ther Adv Respir Dis. 2022;16:17534666221135316.CrossRefPubMedPubMedCentral

32.

Hyldgaard C, Bendstrup E, Wells AU, Hilberg O. Unclassifiable interstitial lung diseases: clinical characteristics and survival. Respirology. 2017;22:494–500.CrossRefPubMed

33.

Brusca RM, Pinal-Fernandez I, Psoter K, Paik JJ, Albayda J, Mecoli C, Tiniakou E, Mammen AL, Christopher-Stine L, Danoff S, Johnson C. The ILD-GAP risk prediction model performs poorly in myositis-associated interstitial lung disease. Respir Med. 2019;150:63–5.CrossRefPubMedPubMedCentral

34.

Kondoh S, Chiba H, Nishikiori H, Umeda Y, Kuronuma K, Otsuka M, Yamada G, Ohnishi H, Mori M, Kondoh Y, Taniguchi H, Homma S, Takahashi H. Validation of the Japanese disease severity classification and the GAP model in Japanese patients with idiopathic pulmonary fibrosis. Respir Investig. 2016;54:327–33.CrossRefPubMed

35.

Kim ES, Choi SM, Lee J, Park YS, Lee CH, Yim JJ, Yoo CG, Kim YW, Han SK, Lee SM. Validation of the GAP score in Korean patients with idiopathic pulmonary fibrosis. Chest. 2015;147:430–7.CrossRefPubMed

Title: ILD-GAP combined with the monocyte ratio could be a better prognostic prediction model than ILD-GAP in patients with interstitial lung diseases
Authors: Momo Hirata
Yu Hara
Hiroaki Fujii
Kota Murohashi
Yusuke Saigusa
Shiqi Zhao
Miyu Kobayashi
Ryo Nagasawa
Yoichi Tagami
Ami Izawa
Yukiko Otsu
Keisuke Watanabe
Nobuyuki Horita
Nobuaki Kobayashi
Takeshi Kaneko
Publication date: 01-12-2024
Publisher: BioMed Central
Keywords: Idiopathic Pulmonary Fibrosis
Pneumonia
Published in: BMC Pulmonary Medicine / Issue 1/2024
Electronic ISSN: 1471-2466
DOI: https://doi.org/10.1186/s12890-023-02833-6

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2024

Patient education needs in severe asthma, a pilot study

Lung transcriptomics reveals the underlying mechanism by which aerobic training enhances pulmonary function in chronic obstructive pulmonary disease

Immature central tumor tertiary lymphoid structures are associated with better prognosis in non-small cell lung cancer

Do middle-aged patients with onset of idiopathic scoliosis before the age of 10 years who have reduced pulmonary function have a risk for rapid decline – a comparative study

Case report of a novel alpha1-antitrypsin null variant in Türkiye: Q0RİZE

A case with multiple nodules and mucosal oedema of the trachea and both bronchi induced by IgG4-related disease

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials